Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02583672 · ClinicalTrials.gov registry record · Phase 2
Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02583672 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 33 participants.
The verdict
NCT02583672, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to measure levels of blood and brain chemicals related to oxidative stress and inflammation in healthy volunteers and individuals with Type 1 Gaucher disease (GD1) to see if these levels are altered by GD1.
Interventions
- DRUG N-acetylcysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-09 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02583672
The ClinicalTrials.gov registry entry for NCT02583672 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which N-acetylcysteine is the first listed.
NCT02583672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02583672 about?
NCT02583672 is a clinical study titled "Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)". The purpose of this study is to measure levels of blood and brain chemicals related to oxidative stress and inflammation in healthy volunteers and individuals with Type 1 Gaucher disease (GD1) to see if these levels are altered by GD1.
What is the current status of trial NCT02583672?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2015-09. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT02583672?
The interventions under investigation include: N-acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT02583672?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.